

Vivek Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9278490/publications.pdf>

Version: 2024-02-01

76
papers

15,996
citations

430874

18
h-index

128289

60
g-index

78
all docs

78
docs citations

78
times ranked

17905
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3
2	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
3	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	1.9	10
4	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 406-406.	1.6	0
5	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
6	Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e449-e455.	0.4	19
7	Clinical course and outcome among patients with acute pancreatitis and COVID-19. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 695-700.	1.6	19
8	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
9	Efficacy and safety of primary needle-knife fistulotomy in biliary cannulation. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	1.6	2
10	The global, regional, and national burden of stomach cancer in 195 countries, 1990â€2017: a systematic analysis for the Global Burden of Disease study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 42-54.	8.1	390
11	Connect MM Registry as a national reference for United States multiple myeloma patients. <i>Cancer Medicine</i> , 2020, 9, 35-42.	2.8	14
12	Primary renal lymphoma: A populationâ€based analysis using the SEER program (1973â€2015). <i>European Journal of Haematology</i> , 2020, 104, 390-399.	2.2	16
13	Prediction of Heparin Induced Thrombocytopenia (HIT) Using a Combination of 4Ts Score and Screening Immune Assays. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096285.	1.7	1
14	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	13.7	7,664
15	Global burden of 87 risk factors in 204 countries and territories, 1990â€2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	13.7	3,928
16	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	13.7	890
17	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	6.3	23
18	<p>The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma<p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 11-17.	3.7	64

#	ARTICLE	IF	CITATIONS
19	Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. <i>JCO Oncology Practice</i> , 2020, 16, e341-e349.	2.9	11
20	Epidemiology and Predictors of all-cause 30-Day readmission in patients with sickle cell crisis. <i>Scientific Reports</i> , 2020, 10, 2082.	3.3	22
21	The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 582-597.	8.1	241
22	The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. <i>Oncologist</i> , 2020, 25, 505-514.	3.7	93
23	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2019, 9, 75.	6.2	43
24	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	7.1	1,691
25	Radiation Recall Dermatitis Consecutive to Cabozantinib Use. <i>American Journal of Therapeutics</i> , 2019, 26, e559-e561.	0.9	3
26	Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 435-435.	1.6	9
27	Racial disparities in incidence & survival of Kaposi's sarcoma in the United States. <i>Indian Journal of Medical Research</i> , 2019, 149, 354.	1.0	8
28	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Dana-Farber Cancer Institute (DFCI) experience. <i>Journal of Clinical Oncology</i> , 2019, 37, e16037-e16037.	1.6	0
29	Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer. <i>World Journal of Clinical Oncology</i> , 2019, 10, 201-212.	2.3	0
30	A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM). <i>Blood</i> , 2019, 134, 4779-4779.	1.4	1
31	Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes. <i>Blood</i> , 2019, 134, 3494-3494.	1.4	0
32	Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor. <i>American Journal of Therapeutics</i> , 2018, 25, e508-e509.	0.9	3
33	Intravenous Immunoglobulin-Induced Profound Bradycardia in a Patient With Idiopathic Thrombocytopenic Purpura. <i>American Journal of Therapeutics</i> , 2018, 25, e572-e574.	0.9	9
34	Syndrome of Inappropriate Antidiuretic Hormone Consecutive to treatment with Ciprofloxacin. <i>American Journal of Therapeutics</i> , 2018, 25, e684-e685.	0.9	3
35	Emerging Therapies in the Management of Advanced-Stage Gastric Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 404.	3.5	24
36	RASMUSSEN ANEURYSM: A RARE CAUSE OF LIFE-THREATENING HEMOPTYSIS. <i>Chest</i> , 2018, 154, 683A.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Recent Advances in Diffuse Large B Cell Lymphoma. , 2018, , .		2
38	Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis. American Journal of Therapeutics, 2018, 25, e740-e741.	0.9	2
39	A case series of Kimura's disease: a diagnostic challenge. Therapeutic Advances in Hematology, 2018, 9, 207-211.	2.5	17
40	A Comparative Study of Primary Adenoid Cystic and Mucoepidermoid Carcinoma of Lung. Frontiers in Oncology, 2018, 8, 153.	2.8	23
41	Changing pattern of secondary cancers among patients with malignant thymoma in the USA. Future Oncology, 2018, 14, 1943-1951.	2.4	7
42	Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 576-589.e1.	0.4	10
43	An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. PeerJ, 2018, 6, e4342.	2.0	16
44	Implementation of an oral chemotherapy adherence tracking program at a medically underserved comprehensive community cancer center.. Journal of Clinical Oncology, 2018, 36, e18873-e18873.	1.6	0
45	Oral chemotherapy adherence tracking program implementation at a medically underserved comprehensive community cancer center.. Journal of Clinical Oncology, 2018, 36, 294-294.	1.6	0
46	Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL). Blood, 2018, 132, 4869-4869.	1.4	0
47	Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States. Blood, 2018, 132, 4861-4861.	1.4	0
48	Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US). Blood, 2018, 132, 4765-4765.	1.4	0
49	Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care. Blood, 2018, 132, 4764-4764.	1.4	0
50	Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States. Blood, 2018, 132, 4868-4868.	1.4	0
51	Unusual Presentation of Diffuse Large B-Cell Lymphoma With Splenic Infarcts. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961769074.	0.6	4
52	Suicide Rates in Cancer Patients in the Current Era in United States. The American Journal of Psychiatry Residents' Journal, 2017, 12, 11-14.	0.3	14
53	Chronic Lymphocytic Leukemia: A Rare Cause of Pathological Fracture of the Femur. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961773513.	0.6	4
54	Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab. Immunotherapy, 2017, 9, 955-961.	2.0	34

#	ARTICLE	IF	CITATIONS
55	The pattern of secondary cancers in patients with Kaposi sarcoma in the United States. <i>Cancer Causes and Control</i> , 2017, 28, 1065-1074.	1.8	5
56	Infliximab Therapy Leading to Pulmonary Tuberculosis in a Patient With Negative Interferon \hat{I}^3 Release Assay (IGRA)-Based QuantiFERON Gold Test. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961771754.	0.6	3
57	Kaposi Sarcoma Mimicking Acute Flare of Ulcerative Colitis. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961771351.	0.6	10
58	Authenticity and Reliability of the Cardiac Monitor Alarms in the ICU: A Patient Safety Concern Due to Alarm Fatigue. <i>Chest</i> , 2017, 152, A566.	0.8	1
59	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 49.	3.5	459
60	Systemic Cystic Angiomatosis Mimicking Metastatic Cancer: A Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , 2017, 2017, 1-5.	0.7	7
61	Prevalence and characteristics of hereditary non-polyposis colorectal cancer (HNPCC) syndrome in immigrant Asian colorectal cancer patients. <i>BMC Cancer</i> , 2017, 17, 843.	2.6	15
62	Penoscrotal haematoma after cardiac catheterisation. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2016-218934.	0.5	2
63	Evaluating the role of massage therapy on patient caregivers in a comprehensive community cancer center.. <i>Journal of Clinical Oncology</i> , 2017, 35, 25-25.	1.6	3
64	Integration of spiritual care services along with supportive care clinic in a comprehensive community cancer center.. <i>Journal of Clinical Oncology</i> , 2017, 35, 181-181.	1.6	1
65	Secondary Cancers in Hodgkin Lymphoma: A Comprehensive Analysis of Incidence and Trends in Survivors. <i>Blood</i> , 2017, 130, 913-913.	1.4	1
66	Challenges to Palliative Care in Pediatric Patients. <i>Journal of Palliative Care & Medicine</i> , 2016, 06, .	0.1	1
67	Hereditary angioedema (HAE): a cause for recurrent abdominal pain. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217196.	0.5	8
68	Aortic valve fibroelastoma: a rare cause of stroke. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217631.	0.5	7
69	Primary Cns Lymphoma: Current Diagnosis and Management. <i>Journal of Cancer Prevention & Current Research</i> , 2016, 4, .	0.1	0
70	The incidence, prognosis and survival of primary breast lymphoma: A SEER experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19026-e19026.	1.6	0
71	Ataxia in long term survivors of lung cancer after whole brain radiation therapy (WBRT).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20656-e20656.	1.6	3
72	Subsequent cancers in the long term survivors of Hodgkinâ€™s lymphoma: A SEER based analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19014-e19014.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who received neoadjuvant treatment for advanced ovarian cancer.. Journal of Clinical Oncology, 2016, 34, e17054-e17054.	1.6	0
74	Risk of Developing Second Cancers in Plasmacytoma in United States. Blood, 2016, 128, 4443-4443.	1.4	0
75	The performance of NLST screening criteria in Asian lung cancer patients. BMC Cancer, 2015, 15, 916.	2.6	13
76	Unusual Presentation of Metastatic Sebaceous Crcinoma and Its Response to Chemotherapy: Is Genotyping a Right Answer for Guiding Chemotherapy in Rare Tumours?. Current Oncology, 2015, 22, 316-319.	2.2	22